Implantable cardioverter defibrillator: Ventritex Cadence

Area of Science:

• Cardiology
• Biomedical Engineering
• Medical Devices

Background:

• Ventricular tachyarrhythmias pose a significant risk to patients.
• Existing defibrillator technology has limitations in efficacy and patient management.
• Third-generation implantable antitachyarrhythmia devices are needed.

Purpose of the Study:

• To evaluate the capabilities of the Ventritex Cadence Model V-100 Tiered Therapy Defibrillator.
• To assess the potential of this device to improve treatment for ventricular tachyarrhythmias.

Main Methods:

• The study focuses on the features of the Ventritex Cadence Model V-100, a third-generation implantable pulse generator.
• Device capabilities include high-energy defibrillation, low-energy cardioversion, antitachycardia pacing, and bradycardia pacing.
• The device utilizes microprocessor control for monophasic or biphasic shocks and features noncommitted shock delivery and electrogram storage.

Main Results:

• The Ventritex Cadence Model V-100 demonstrates expanded capabilities compared to previous generations.
• Features include high-energy defibrillation, low-energy cardioversion, and advanced pacing options.
• Noncommitted shock delivery and electrogram storage enhance therapeutic control and data acquisition.

Conclusions:

• The Ventritex Cadence Model V-100 represents a significant advancement in treating ventricular tachyarrhythmias.
• Its enhanced features are expected to improve therapy efficacy and patient management.
• Further clinical trials are underway to confirm these benefits.